Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe Sells 11,581 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 11,581 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $43.01, for a total value of $498,098.81. Following the sale, the chief financial officer now owns 107,789 shares of the company’s stock, valued at $4,636,004.89. The trade was a 9.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Oluyemi Okupe also recently made the following trade(s):

• On Tuesday, February 4th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $38.92, for a total value of $450,732.52.
• On Monday, January 13th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $24.44, for a total value of $283,039.64.
• On Thursday, December 26th, Oluyemi Okupe sold 4,213 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.98, for a total value of $126,305.74.
• On Friday, December 20th, Oluyemi Okupe sold 18,959 shares of Hims & Hers Health stock. The stock was sold at an average price of $25.77, for a total value of $488,573.43.
• On Monday, November 25th, Oluyemi Okupe sold 101,993 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.62, for a total value of $3,021,032.66.
• On Wednesday, November 13th, Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.93, for a total value of $4,276,577.98.

Hims & Hers Health Stock Down 2.7 %

NYSE HIMS traded down $1.21 during trading on Tuesday, hitting $43.56. The company’s stock had a trading volume of 7,309,816 shares, compared to its average volume of 11,847,643. The firm has a 50 day moving average price of $30.50 and a 200 day moving average price of $23.43. The firm has a market cap of $9.52 billion, a P/E ratio of 99.01 and a beta of 1.35. Hims & Hers Health, Inc. has a 52 week low of $9.14 and a 52 week high of $46.01.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in HIMS. SlateStone Wealth LLC grew its holdings in shares of Hims & Hers Health by 4.0% during the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock worth $257,000 after purchasing an additional 413 shares in the last quarter. Blume Capital Management Inc. grew its holdings in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 600 shares in the last quarter. Quest Partners LLC grew its holdings in shares of Hims & Hers Health by 22.6% during the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after purchasing an additional 807 shares in the last quarter. Harbour Investments Inc. grew its holdings in shares of Hims & Hers Health by 18.8% during the 4th quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock worth $127,000 after purchasing an additional 833 shares in the last quarter. Finally, Stonekeep Investments LLC grew its holdings in shares of Hims & Hers Health by 5.5% during the 4th quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock worth $410,000 after purchasing an additional 882 shares in the last quarter. 63.52% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on HIMS. Deutsche Bank Aktiengesellschaft raised their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Canaccord Genuity Group raised their price target on Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd. Needham & Company LLC raised their price objective on Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, January 6th. TD Cowen reissued a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Finally, Piper Sandler raised their price objective on Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a research note on Monday, January 6th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $25.13.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.